In-vivo tumor kinetics in response to αCTLA4 immune checkpoint blockade therapy to show the efficacy of transplanted engineered lymph nodes.
HNSCC mice, a mice model developed by injection of 4MOSC1 cell line, were sedated and underwent micro-incision neck surgery for lymph node extraction. In sham surgeries, the same extracted lymph node was reinserted, while transplantation surgeries involved our engineered lymph node. The mice then received immune checkpoint blockade therapy through injection of anti-CTLA4. The tumor volume in each mouse was tracked to assess the surgical outcomes and tumor development kinetics.
For mice without neck dissection, the tumor should regress completely upon injection of 𝜶CTLA4 (Blue).
The mice with neck dissection, including ablation of lymph nodes, which was a surgical procedure mimicking the standard care of treatment for HNSCC patients, had their tumor volume continue to increase after the injection of 𝜶CTLA4 (Green).
The mice transplanted with our decellularized lymph node after neck dissection were able to exhibit complete tumor regression with a similar rate as the native mice (Red), indicating the 𝜶CTLA4 response was completely rescued.
The engineered lymph node was able to rescue αCTLA4 anti-rumor response to a similar level as the native lymph node.